42 reports

Pharmaceutical Drugs are widely used for treating a multitude of diseases like cough, cold, diabetes, cancer, HIV, headache, viral fever, nausea, typhoid, tuberculosis, tumor, heart attack, hyper tension, depression, etc.

  • Biosimilar
  • Amgen Inc.
  • Celltrion, Inc.
  • Pfizer Inc.
  • Sandoz Inc.
  • PERCENTAGE OF PATIENTS EXPERIENCING ADVERSE EVENTS WITH INFLIXIMAB BIOSIMILARS

Anti-TNF-α biologic drugs have BEEN ASSOCIATED WITH RECURRENCE OF TUBERCULOSIS, AS WELL AS SYSTEMIC FUNGAL INFECTIONS SUCH AS HISTOPLASMOSIS.

  • Biosimilar
  • Epidemiology
  • Europe
  • Pfizer Inc.
  • Remicade group

Enbrel has a boxed warning in its package insert noting an increased risk of cancer malignancies, tuberculosis, reactivation of tuberculosis, and other opportunistic infections associated with its use.

  • Biosimilar
  • World
  • Amgen Inc.
  • Merck & Co., Inc.
  • Novartis AG

RECOMMENDATIONS FOR SCREENING FOR TUBERCULOSIS (TB) IN PATIENTS GIVEN BIOLOGICS OR XELJANZ, RECOMMENDATIONS FOR VACCINATIONS IN PATIENTS RECEIVING DMARDS OR BIOLOGICS, AS WELL AS RECOMMENDATIONS FOR THE LABORATORY MONITORING OF TRADITIONAL DMARDS ARE ALSO OF NOTE.

  • Biosimilar
  • AbbVie Inc.
  • Astellas Pharma Inc.
  • Pfizer Inc.
  • Remicade group

The tuberculosis occurrence rate is extremely low, but if it does occur it has severe implications. "

  • Biosimilar
  • Amgen Inc.
  • Can-Fite BioPharma Ltd.
  • Merck & Co., Inc.
  • Pfizer Inc.

The tuberculosis occurrence rate is extremely low, but if it does occur it has severe implications. "

  • Biosimilar
  • Amgen Inc.
  • Can-Fite BioPharma Ltd.
  • Merck & Co., Inc.
  • Pfizer Inc.

The tuberculosis occurrence rate is extremely low, but if it does occur it has severe implications. "

  • Biosimilar
  • Amgen Inc.
  • Can-Fite BioPharma Ltd.
  • Merck & Co., Inc.
  • Pfizer Inc.

The tuberculosis occurrence rate is extremely low, but if it does occur it has severe implications. "

  • Biosimilar
  • Amgen Inc.
  • Can-Fite BioPharma Ltd.
  • Merck & Co., Inc.
  • Pfizer Inc.

Alongside their wide range of medical uses, there are side effects, such as, cancer, tuberculosis, fungal infections and other opportunistic infections that are caused due to prolonged use of these drugs.

  • Biosimilar
  • Biocon Limited
  • Hospira, Inc.
  • Mylan Inc.
  • Sandoz Inc.

THE BOXED WARNING IN THE HUMIRA PACKAGE INSERT NOTES AN INCREASED RISK OF CANCER, TUBERCULOSIS (TB), AND OTHER OPPORTUNISTIC INFECTIONS ASSOCIATED WITH ITS USE.

  • Biosimilar
  • AbbVie Inc.
  • Amgen Inc.
  • Pfizer Inc.
  • Remicade group

No. ## Product Name TUBERCULOSIS RECOMBINANT SUBUNIT VACCINE V## (PNEUMOCONJUGATE-## VACCINE) NDV-## Company SANOFI ## ## Indication TUBERCULOSIS PNEUMOCOCCAL INFECTIONS STAPHYLOCOCCAL INFECTIONS, CANDIDIASIS MERCK NOVADIGM THERAPEUTICS IM IM Phase of Development PHASE II RoA IM PH

  • Biosimilar
  • World
  • Market Size
  • Gerresheimer AG
  • West Pharmaceutical Services, Inc.

E N B R E L ( E T A N E R C E P T; AMGEN/ PFIZER/ TAKEDA/ GLAXOSMITHKLINE) IS PREFERRED FOR PATIENTS AT HIGH RISK OF RE-ACTIVATION OF TUBERCULOSIS.

  • Biosimilar
  • Therapy
  • Europe
  • Spain
  • ESI Group

INLEUSIN IS USED IN THE TREATMENT OF RENAL CELL CARCINOMA (KIDNEY CANCER), METASTATIC MELANOMA (SKIN CANCER), AND THORATIC FLUID BUILD-UP CAUSED BY CANCER AND TUBERCULOSIS.

  • Biosimilar
  • Europe
  • World
  • Roche Group
  • Sandoz Inc.
  • BIOSIMILARS MARKET SIZE FOR INFECTIOUS DISEASES, BY REGION, 2014-2021 (USD MILLION)
  • 8.6 INFECTIOUS DISEASES

Infectious diseases include cholera, hepatitis, tuberculosis, and influenza.

  • Biosimilar
  • Europe
  • World
  • Market Size
  • Sandoz Inc.

It undertakes extensive research and development of pharmaceuticals for treatment of migraine, gastrointestinal, psoriasis, central nervous system, cardiovascular, tuberculosis, diabetes and inflammation.

  • Biosimilar
  • Pharmaceutical
  • United States
  • Product Initiative
  • Coherus BioSciences, Inc.
  • NEUTROPENIA - PIPELINE BY LUPIN LTD, H1 2017

The company undertakes extensive research and development of pharmaceuticals for treatment of migraine, gastrointestinal, psoriasis, central nervous system, cardiovascular, tuberculosis, diabetes and inflammation.

  • Biosimilar
  • Pharmaceutical
  • United States
  • Product Initiative
  • Coherus BioSciences, Inc.
  • Aug 30, 2016: FDA approves Erelzi, a biosimilar to Enbrel
  • JUN 27, 2017: SANDOZ RECEIVES APPROVAL IN EUROPE FOR ERELZI (BIOSIMILAR ETANERCEPT) TO TREAT MULTIPLE INFLAMMATORY DISEASES

There were no cases of tuberculosis or gastrointestinal perforations.

  • Autoimmune Disease
  • Biosimilar
  • Monoclonal Antibody
  • United States
  • Product Initiative

Strides Shasun' s products find applications in the treatment of diseases such as AIDS, malaria and tuberculosis.

  • Biosimilar
  • Pharmaceutical
  • United States
  • Company
  • Oncobiologics, Inc.
  • LICENSING AGREEMENTS

Strides Shasun' s products find applications in the treatment of diseases such as AIDS, malaria and tuberculosis.

  • Biosimilar
  • Pharmaceutical
  • United States
  • Company
  • Pfenex Inc.
  • Biosimilar
  • Musculoskeletal Disorder
  • United States
  • Product Initiative
  • Pfizer Inc.
  • Aug 30, 2016: FDA approves Erelzi, a biosimilar to Enbrel

Erelzi contains a Boxed Warning to alert health care professionals and patients about an increased risk of serious infections leading to hospitalization or death, including tuberculosis, invasive fungal infections (such as histoplasmosis) and others.

  • Biosimilar
  • Monoclonal Antibody
  • Musculoskeletal Disorder
  • Research And Development
  • Coherus BioSciences, Inc.

No cases of tuberculosis or lymphoma were observed through week ##, and there was no increased risk of cardiovascular events or serious opportunistic infection.

  • Autoimmune Disease
  • Biosimilar
  • Monoclonal Antibody
  • Therapy
  • United States

No cases of tuberculosis or lymphoma were observed through week ##, and there was no increased risk of cardiovascular events or serious opportunistic infection.

  • Autoimmune Disease
  • Biosimilar
  • Monoclonal Antibody
  • Therapy
  • United States

The company' s project pipeline includes products with therapeutic application in the area of diabetes type II, leishmaniasis, and tuberculosis.

  • Biosimilar
  • Hospital
  • Monoclonal Antibody
  • Therapy
  • OncoSec Medical Incorporated

The committee recommended conducting the clinical trial by including Mantoux test at baseline screening of latent tuberculosis to exclude the tuberculosis patients in addition to the other tests.

  • Biosimilar
  • Monoclonal Antibody
  • Musculoskeletal Disorder
  • Research And Development
  • Pfizer Inc.

NO CASES OF TUBERCULOSIS OR SPONTANEOUS GASTROINTESTINAL PERFORATION WERE REPORTED DURING THE STUDY.

  • Arthritis
  • Biosimilar
  • R&D
  • Research And Development
  • Pfizer Inc.

TUBERCULOSIS (TB) FUNGAL MALARIA VIRAL COMMON COLD CYTOMEGALOVIRUS EBOLA B C HERPES SIMPLEX HIV INFLUENZA POLIO RESPIRATORY SYNCYTIAL VIRUS (RSV) ZIKA METABOLIC DIABETES DATE PARTIES STAGE VALUE US$M SUBJECT CONTRACT MEDICINES JOINT VENTURE AGREEMENT FOR COMMERCIALIZATION OF SEP 2016 NEMAUR

  • Biosimilar
  • Biotech
  • Pharmaceutical
  • Deals & Alliance
  • Wildwood Ventures Limited
  • Phase III - Trial Details
  • Arthritis
  • Biosimilar
  • Pathology
  • Research And Development
  • Pfizer Inc.

TUBERCULOSIS, M.

  • Biosimilar
  • Monoclonal Antibody
  • Therapy
  • United States
  • Product Initiative

For serious AEs the ER/ ##PY was ##. ##, and for serious infections it was ##. ##, with ## confirmed case of active tuberculosis.

  • Biosimilar
  • Therapy
  • Company
  • Product Initiative
  • Pfizer Inc.